Doctors use new diagnostic tool to take up fighting against cancer

World Today

smoking

Thanks to some cutting-edge technology, medical companies in the U.S. and China are teaming up to better diagnose the cancer and similar disease.

CGTN’s Hendrik Sybrandy reports.

Gary Pestano of the Colorado-based diagnostics company Biodesix believes a new collaboration that could benefit countless people in China; a refrigerator-sized device will help patients with lung cancer pick treatments that best fit them.

According to Pestano, they can get that from a single drop of blood.

That’s due partly to a higher incidence of smoking, and the presence of smog, non-small cell lung cancer, which makes up the large majority of lung cancers on the rise in China. Biodesix said the company’s Veristrat test and China-based Bioyong and its analytical technology pair up well.

By commercializing Veristrat, a precision protein-based blood test, Bioyong will help Chinese doctors determine which lung cancer patients are unlikely to respond to the usual standard of care like chemotherapy – eliminating treatments that are costly, unnecessary and harmful.

Veristrat still needs approval from China’s Food and Drug Administration. Clinical trials will soon be underway. The test, already used in the U.S., could be helping patients in China by next year.